Tumor-infiltrating lymphocytes and PD-L1 in breast cancer (and, what happened to medullary carcinoma?)
Tumor-infiltrating lymphocytes (TILs) and PD-L1 have emerged as important immune biomarkers in breast cancer, particularly triple negative breast carcinomas (TNBC) and human epidermal growth factor-2 positive (HER-2+) breast carcinomas. These components of the tumor immune microenvironment can be harnessed or targeted with immunotherapy, which represents a significant advancement in the management of TNBC. TILs are a prognostic biomarker in breast cancer, and this recognition has led to reclassification of medullary carcinoma (which were TILs rich by definition) as a pattern of invasive ductal carcinoma (no special type) rather than a distinct histologic type.
Source: Diagnostic Histopathology - Category: Pathology Authors: Ashley Cimino-Mathews Tags: Mini-symposium: Breast pathology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Ductal Carcinoma | Immunotherapy | Pathology